Clik here to view.
Uptick in M&A Activity and Investor Cash Expected to Re-Invigorate Pharma and...
LONDON & BOSTON & TOKYO & SAN FRANCISCO The upward momentum seen in the pharma and biotech sectors during 2017 looks set to continue into 2018, with more novel medicines set to hit the...
View ArticleClik here to view.
Rhythmlink Launches FDA Cleared MR Conditional*/CT Quick Connect System™...
COLUMBIA, S.C. Rhythmlink International, LLC has announced the release of a new product line designed to maximize efficiency and workflow when recording EEG on patients who require MR or CT imaging....
View ArticleClik here to view.
Orthocell Commences Treatment of Its 1,000th Patient
PERTH, Australia Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce that it has commenced treatment of its 1,000th patient, in its TGA...
View ArticleClik here to view.
Genentech’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in...
SOUTH SAN FRANCISCO, Calif. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive interim results from the Phase III HAVEN 4 study evaluating HEMLIBRA®...
View ArticleClik here to view.
Median Technologies Inks a Research Collaboration Agreement for Lung Cancer...
SOPHIA ANTIPOLIS, France Regulatory News: Median Technologies (Paris:ALMDT), The Imaging Phenomics Company® (Paris:ALMDT) announces today a research collaboration agreement with Xingtai People’s...
View ArticleClik here to view.
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1...
CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash. Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3...
View ArticleClik here to view.
ベルタンとザイモリサーチが新しい連携を発表
米カリフォルニア州アーバイン & メリーランド州ロックビル （ビジネスワイヤ） — ザイモリサーチ・コープとベルタンは、マイクロバイオームワークフローにおけるサンプル溶解処置を完全でバイアスのないものとする連携を発表します。ZymoBIOMICS®微生物叢標準品およびDNA精製用ZymoBIOMICS...
View ArticleClik here to view.
Bertin与Zymo Research宣布达成新的合作
加州尔湾和马里兰州罗克韦尔 (美国商业资讯) — Zymo Research Corp.与Bertin宣布一项合作，共同确保微生物圈工作流程中的样品溶解步骤完整无偏差。一份应用备注已经发布，其描述了材料、步骤和采用Precellys® Evolution...
View ArticleClik here to view.
ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu...
LAUSANNE, Schweiz ADC Therapeutics (ADCT), ein onkologisches Biotech-Unternehmen, das sich auf die Entwicklung von geschützten Antikörper-Wirkstoff-Konjugaten (Antibody Drug Conjugates, ADCs) zur...
View ArticleClik here to view.
Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
GAITHERSBURG, Md. Valneva SE, a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, today announced that its subsidiary Intercell USA, Inc. has...
View ArticleClik here to view.
ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
スイス・ローザンヌ （ビジネスワイヤ） — 主要ながんを標的にした専有的な抗体薬物複合体（ADC）の開発を専門とするオンコロジー創薬／開発企業のADCセラピューティクス（ADCT）は本日、リンパ腫と白血病の重要な亜型でADCT-301（camidanlumab...
View ArticleClik here to view.
武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据，该试验评估ADCETRIS® (brentuximab...
马萨诸塞州剑桥、日本大阪和华盛顿州博瑟尔 (美国商业资讯) – 武田药品工业株式会社(TSE:4502)和Seattle Genetics, Inc. (NASDAQ: SGEN)今天宣布，3期ECHELON-1临床试验的数据将于2017年12月10日星期天在第59届美国血液学会(ASH)年会的全体科学会议上呈报，该项试验评估ADCETRIS (brentuximab...
View ArticleClik here to view.
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with...
TOKYO, BASKING RIDGE, N.J. & LOS ANGELES Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc. (Nasdaq: PBYI) have announced a preclinical research...
View ArticleClik here to view.
Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for...
CAMBRIDGE, Mass. Vedanta Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined...
View ArticleClik here to view.
ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
スイス・ローザンヌ （ビジネスワイヤ） — 主要ながんを標的にした専有的な抗体薬物複合体（ADC）の開発を専門とするオンコロジー創薬／開発企業のADCセラピューティクス（ADCT）は本日、リンパ腫と白血病の重要な亜型でADCT-402（loncastuximab...
View ArticleClik here to view.
Corindus Announces First Commercial Installation of CorPath® GRX System...
WALTHAM, Mass. Corindus Vascular Robotics, Inc.(NYSE American: CVRS), a leading developer of precision vascular robotics, announced today the first commercial installation of a CorPath GRX System...
View ArticleClik here to view.
三叶草生物制药完成6,280万元人民币A轮融资
成都 三叶草生物制药，一家致力于创新及变革性生物制药研发的生物制药公司，今天宣布完成6,280万元人民币（约合950万美元）的A轮融资。 结合其他非稀释性资金来源，此次融资将三叶草2017年获得的资金总额达到8,430万元人民币（约合1,270万美元）。此 A轮融资由四川天河生物医药产业创业投资基金作为领投者。...
View ArticleClik here to view.
Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
CHENGDU, China Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced the completion of a RMB 62.8 million...
View ArticleClik here to view.
Orthocell Granted European Tendon Regeneration Patent
PERTH, Australia Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has been granted a key European Patent. The patent is entitled...
View ArticleClik here to view.
Chi-Med Initiates Fruquintinib U.S. Clinical Trials
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent...
View Article